Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label, long‐term extension study

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2012-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2012.01620.xPMID 22583697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.

  2011cited by this paper
• Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes

  2011cited by this paper
• Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study

  2011cited by this paper
• DPP‐4 inhibition and islet function

  2011cited by this paper
• Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

  2011cited by this paper
• Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

  2011cited by this paper
• Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

  2011cited by this paper
• Dipeptidyl Peptidase‐4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP‐1

  2010influential reference
• Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

  2010cited by this paper
• Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

  2010cited by this paper
• GIP and GLP‐1, the two incretin hormones: Similarities and differences

  2010cited by this paper
• Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with type 2 diabetes mellitus

  2010cited by this paper
• Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naïve Patients With Type 2 Diabetes

  2010cited by this paper
• Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice

  2009cited by this paper
• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

  2009cited by this paper
• Hypoglycaemia with Oral Antidiabetic Drugs

  2009cited by this paper
• Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  2009cited by this paper
• Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycaemia

  2009cited by this paper
• Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study

  2009influential reference
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

  2009cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

  2009cited by this paper
• Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia

  2008cited by this paper
• Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control

  2008cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care

  2006cited by this paper
• Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

  2003cited by this paper
• ICH Harmonised Tripartite Guideline: guideline for good clinical practice.

  2001cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• UKPDS 26: sulphonylurea failure in non‐insulin‐dependent diabetic patients over six years

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

  1997cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Task force.

  1974cited by this paper

• Comparative effectiveness of metformin and alogliptin combination therapy versus metformin monotherapy in patients with type 2 diabetes: an emulated target trial

  2025cites this paper
• Metformin for the Treatment of Type 2 Diabetes in Asian Adults: A Systematic Review

  2025cites this paper
• Dipeptidyl Peptidase-4 Inhibitors Improved Lipid Levels in Patients With Type 2 Diabetes: A Meta-analysis of Randomized Clinical Trials.

  2025cites this paper
• Metformin-Associated Gastrointestinal Adverse Events Are Reduced by Probiotics: A Meta-Analysis

  2024cites this paper
• Retagliptin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial

  2024influential citation
• Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment

  2022cites this paper
• Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/Metformin Combination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type 2 Diabetes

  2022cites this paper
• Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes

  2021cites this paper
• Reduction in HbA1c with SGLT2 inhibitors vs DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials.

  2020cites this paper
• Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus

  2020cites this paper
• DPP4 inhibitors and respiratory infection, a systematic review and meta-analysis of the CardioVascular Outcomes Trials conducted before the pandemic and implications for the management of diabetes during COVID-19

  2020cites this paper
• Incretin mimetics and sodium-glucose co-transporter 2 inhibitors as monotherapy or add-on to metformin for treatment of type 2 diabetes: a systematic review and network meta-analysis

  2020cites this paper
• Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus

  2019cites this paper
• Risk of any hypoglycaemia with newer antihyperglycaemic agents in patients with type 2 diabetes: A systematic review and meta‐analysis

  2019cites this paper
• Diabetic Pharmacotherapies in Kidney Disease

  2019cites this paper
• Reliable choice in therapy of type 2 diabetes mellitus: focus on alogliptin

  2019cites this paper
• An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

  2019cites this paper
• Efficacy and safety of fixed‐dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial

  2017cites this paper
• Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions

  2017cites this paper
• Efficacy and safety of combination therapy with an α‐glucosidase inhibitor and a dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta‐analysis

  2017cites this paper
• Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials

  2017cites this paper
• Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.

  2017cites this paper
• A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control

  2017cites this paper
• Ethnic Differences in Efficacy and Safety of Alogliptin: A Systematic Review and Meta-Analysis

  2017cites this paper
• Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double‐blind placebo‐controlled Phase 3 study in mainland China, Taiwan, and Hong Kong

  2017cites this paper
• Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients

  2017cites this paper
• Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation

  2016cites this paper
• DPP‐4 inhibitors and risk of infections: a meta‐analysis of randomized controlled trials

  2016cites this paper
• Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus

  2016influential citation
• Combined use of dipeptidyl peptidase-4 inhibitors and metformin reduces blood sugar level and improves pancreatic islet β cell function in the treatment of type 2 diabetes mellitus : a meta-analysis

  2016cites this paper
• Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis

  2016cites this paper
• Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

  2016cites this paper
• Update on the treatment of type 2 diabetes mellitus.

  2016influential citation
• Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

  2016cites this paper
• Predictors of efficacy of GLP-1 agonists and DPP-4 inhibitors: A systematic review.

  2016cites this paper
• Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis

  2016cites this paper
• Emerging options for the treatment of type 2 diabetes in Chinese patients: focus on arterial function and alogliptin

  2015cites this paper
• Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  2015influential citation
• Incretin System in the Pathogenesis of Type 2 Diabetes and the Role of Incretin Based Therapies in the Management of Type 2 Diabetes

  2015cites this paper
• Incretin-based therapies.

  2015cites this paper
• Alogliptin benzoate for management of type 2 diabetes

  2015cites this paper
• Analyzing the Factors Contributing to Withdrawal from Insulin Therapy Following Additional Administration of Alogliptin: Retrospective Study after Removing Glucotoxicity with Insulin

  2015cites this paper
• A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients

  2015cites this paper
• Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

  2015cites this paper
• Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on β‐cell function in Asian and Caucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对β细胞功能的影响：一项meta分析

  2015cites this paper
• Incretin-based therapies for obesity treatment.

  2015cites this paper
• The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors

  2014cites this paper
• Alogliptin for the treatment of Type 2 diabetes

  2014cites this paper
• Alogliptin for treatment of type 2 diabetes

  2014cites this paper
• Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.

  2014cites this paper
• Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors

  2014cites this paper
• Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase

  2014cites this paper
• Alogliptin benzoate for the treatment of type 2 diabetes

  2014influential citation
• The safety of dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta‐analysis

  2014cites this paper
• Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus

  2014cites this paper
• Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

  2014cites this paper
• Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

  2014influential citation
• Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

  2014influential citation
• Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison

  2014cites this paper
• Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review

  2014cites this paper
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

  2013cites this paper
• Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients

  2013cites this paper
• The Place of GLP-1–Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists

  2013cites this paper
• Alogliptin, but not voglibose, ameliorates dyslipidemia and LDL particle size in patients with impaired glucose tolerance or Type 2 diabetes

  2013cites this paper
• Alogliptin

  2013cites this paper
• Alogliptin

  2013influential citation
• Efficacy of alogliptin, a dipeptidyl peptidase‐4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) – receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes

  2013cites this paper
• Enhancing Pancreatic Beta-Cell Regeneration In Vivo with Pioglitazone and Alogliptin

  2013cites this paper
• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  2012influential citation
• Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan

  2012cites this paper
• Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus

  2012cites this paper
• Vascular Health and Risk Management Dovepress Alogliptin Benzoate for Management of Type 2 Diabetes

  year unknowncites this paper